|
Sarcoma
|
0.070 |
Biomarker
|
group |
BEFREE |
The aim of this study was to evaluate the efficacy and safety of apatinib, an oral vascular endothelial growth factor receptor-2 inhibitor, as salvage treatment for advanced bone and soft tissue sarcomas.
|
31305297 |
2019 |
|
Sarcoma
|
0.070 |
Biomarker
|
group |
BEFREE |
Apatinib is a novel vascular endothelial growth factor receptor 2 (VEGFR-2) inhibitor and revealed potential anti-tumor efficacy in some types of sarcomas.
|
31157270 |
2019 |
|
Sarcoma
|
0.070 |
AlteredExpression
|
group |
BEFREE |
As a novel targeted therapy, especially with regard to angiogenesis, apatinib is a new type of small molecule tyrosine kinase inhibitor that selectively targets VEGFR-2 and has shown encouraging anticancer activity in a wide range of malignancies, including gastric cancer, non-small cell lung cancer, breast cancer, hepatocellular carcinoma, and sarcomas.
|
29849960 |
2018 |
|
Sarcoma
|
0.070 |
Biomarker
|
group |
BEFREE |
Phase II trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study.
|
29527631 |
2018 |
|
Sarcoma
|
0.070 |
AlteredExpression
|
group |
BEFREE |
For better understanding cancer pathogenesis and searching a potential target for antineoplastic therapy, the authors have studied mRNA expression profile in tissues from 39 children with histological confirmed malignant sarcomas and from 23 patients with bone and soft tissue nonmalignant lesions. mRNA levels of Angiogenesis-related genes VEGFA (including isoforms of 121, 165, 189), VEGFC, VEGFR-1, VEGFR-2, VEGFR-3, HIF-1α, TF, TFPI-1, TFPI-2, uPA, PAI-1 in pediatric specimens were examined using quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR). uPA, HIF-1α, VEGFR-1, VEGFR-2, VEGFR-3, and VEGFC mRNA levels from nonmalignant tissue were significantly higher than those from cancer tissue.
|
22304008 |
2012 |
|
Sarcoma
|
0.070 |
Biomarker
|
group |
BEFREE |
Inhibitors of the tyrosine kinase receptors, such as IGF-1R, c-kit, PDGFR, VEGFR, or the mTOR signaling pathway, proteasome, angiogenesis, and stress response proteins are under clinical evaluation against sarcomas.
|
19013896 |
2008 |
|
Sarcoma
|
0.070 |
AlteredExpression
|
group |
LHGDN |
Vascular endothelial growth factor overexpression by soft tissue sarcoma cells: implications for tumor growth, metastasis, and chemoresistance.
|
16951193 |
2006 |